Cell & Gene: The Podcast

Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka

Erin Harris

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 27:18

We love to hear from our listeners. Send us a message.

On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and the need for early, integrated planning.

Subscribe to the podcast!
Apple  |  SpotifyYouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.